Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02760329 · ClinicalTrials.gov registry record
Observational Study of Obstructive Lung Disease (NOVELTY)
A clinical trial of Asthma and Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- 12,255
- Enrollment target
- 20
- Study locations
NCT02760329: Completed study of Asthma and Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.
NCT02760329 is a study of Asthma and Chronic Obstructive Pulmonary Disease that has completed, run by AstraZeneca. The registered enrollment target is 12,255 participants, above the 1,531-participant average among 374 other Asthma trials with a reported enrollment target (700% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02760329, a study of Asthma and Chronic Obstructive Pulmonary Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 12,255 participants
- Enrollment target
- 20
- Study locations
Study Summary
The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study which will recruit patients with a diagnosis, or suspected diagnosis, of asthma and/or Chronic Obstructive Pulmonary Disease (COPD). Patients will undergo clinical assessments and receive standard medical care as determined by their treating physician. Patients enrolled in NOVELTY will be followed up yearly by their treating physician for a total duration of three years. In addition, patients will be followed up remotely every 3 months. The NOVELTY study will collect data currently lacking to allow for multinational data collection to fill regional/local gaps and improve comparability across regions.
Primary Outcome
Lung function test
Conditions Studied
Interventions
- PROCEDURE Blood draw
- PROCEDURE Urine
- PROCEDURE Lung function measurements
- PROCEDURE Fractional Exhaled Nitric Oxide (FENO)
Study Locations (20)
Florida
- Research Site - Clearwater
- Research Site - Gainesville
- Research Site - Miami
- Research Site - Miami
- Research Site - Plantation
California
- Research Site - Loma Linda
- Research Site - Long Beach
- Research Site - Roseville
Michigan
- Research Site - Ann Arbor
- Research Site - Buckley
- Research Site - Hamtramck
Colorado
- Research Site - Aurora
- Research Site - Colorado Springs
Illinois
- Research Site - Chicago
- Research Site - Normal
Kansas
- Research Site - Hutchinson
Louisiana
- Research Site - Shreveport
Massachusetts
- Research Site - Fall River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,255 participants |
| Start Date | 2016-07-25 |
| Est. Completion | 2023-05-31 |
What the finished NCT02760329 record still lists
NCT02760329 is an observational study that tracks outcomes without assigning an intervention. Its 12,255 participants enrollment target places it among the larger protocols in the corpus, above the 1,531-participant average among 374 other Asthma trials with a reported enrollment target (700% higher).
The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Blood draw is the first listed.
NCT02760329 names 20 study sites across 10 states, led by Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT02760329 about?
NCT02760329 is a clinical study titled "Observational Study of Obstructive Lung Disease (NOVELTY)". The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study which will recruit patients with a diagnosis, or suspected diagnosis, of asthma and/or Chronic Obstructive Pulmonary...
What is the current status of trial NCT02760329?
This trial is currently completed. The enrollment target is 12,255 participants. The study started on 2016-07-25. Estimated completion is 2023-05-31.
What conditions does trial NCT02760329 study?
This clinical trial studies the following conditions: Asthma, Chronic Obstructive Pulmonary Disease, COPD.
What interventions are being tested in trial NCT02760329?
The interventions under investigation include: Blood draw (PROCEDURE), Urine (PROCEDURE), Lung function measurements (PROCEDURE), Fractional Exhaled Nitric Oxide (FENO) (PROCEDURE).
Who is sponsoring clinical trial NCT02760329?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02760329 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02760329's enrollment target sits among peer trials
12,255 9th of 374 higher than 366 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04888832 · 12,500 participants · NA
The Effect of Work Requirements in SNAP in Virginia
- NCT05452941 · 12,500 participants
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- NCT07069556 · 12,500 participants
ColoSense Post-Approval Study
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI